Link A, Zaharevitz D W, Kunick C
Institut für Pharmazie, Universität Hamburg, Germany.
Pharmazie. 1999 Mar;54(3):163-6.
The bioisosteric replacement of benzene elements in the antitumor lead structures 2 and 3 led to the thienyl substituted 5H-pyrido[3,2-d][1]benzazepin-6(7H)-ones 8a and 8b, the analogous thiolactams 4a and 4b, and the 4H-pyrido[2,3-d]-thieno[3,2-b]azepines 11 and 12 which represent a novel heterocyclic scaffold. The in vitro evaluation of 4a in a cell line based screening revealed a noteworthy antitumor activity and a remarkable selectivity for renal tumor cell lines. The cell line selectivity pattern of 4a differs distinctly from the pattern displayed by standard antitumor agents.
在抗肿瘤先导结构2和3中对苯环进行生物电子等排体替换,得到了噻吩基取代的5H-吡啶并[3,2-d][1]苯并氮杂卓-6(7H)-酮8a和8b、类似的硫内酰胺4a和4b,以及4H-吡啶并[2,3-d]-噻吩并[3,2-b]氮杂卓11和12,它们代表了一种新型杂环骨架。基于细胞系筛选对4a进行的体外评估显示出显著的抗肿瘤活性以及对肾肿瘤细胞系的显著选择性。4a的细胞系选择性模式与标准抗肿瘤药物所显示的模式明显不同。